Undisclosed CD3 TCB
/ CytomX, Astellas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 03, 2024
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
(GlobeNewswire)
- "CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milestone payment to CytomX."
New molecule • Oncology
1 to 1
Of
1
Go to page
1